^
    2d
    μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia. (PubMed, Med)
    μPharma provides rapid (4-h assay), accurate, and automated prediction of drug sensitivity at single-cell resolution using minimal clinical samples, potentially enabling same-day precision oncology decision-making.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • dasatinib
    3d
    A prospective, single-arm, multicenter clinical study of a maintenance regimen comprising Venetoclax combined with Azacitidine for adult patients with newly diagnosed acute myeloid leukemia (non-APL) who have achieved remission following standard induction and consolidation chemotherapy (ChiCTR2500114099)
    P=N/A, N=80, Not yet recruiting, Mianyang Central Hospital; Mianyang Central Hospital
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    3d
    A prospective, multicenter, single-arm clinical study of low-dose Decitabine combined with Venetoclax in the treatment of newly diagnosed high-risk myelodysplastic syndrome patients. (ChiCTR2500114059)
    P=N/A, N=52, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New trial
    |
    Venclexta (venetoclax) • decitabine
    3d
    Gilteritinib plus venetoclax and azacitidine in FLT3-mutated acute myeloid leukemia: a multicenter retrospective cohort study (ChiCTR2500112896)
    P=N/A, N=111, Completed, The first affiliated hospital, Zhejiang University School of Medicine; The first affiliated hospital, Zhejiang University School of Medicine
    New trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine
    3d
    Sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia: a prospective, single-arm, multicenter clinical study (ChiCTR2500112555)
    P=N/A, N=87, Not yet recruiting, Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University
    New trial
    |
    Venclexta (venetoclax) • sorafenib
    3d
    Clinical Study on Efficacy and Safety of G-CSF Combined with Azacitidine and Venetoclax in the Treatment of Adult Acute Myeloid Leukemia (ChiCTR2500112100)
    P=N/A, N=34, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • lisaftoclax (APG-2575)
    3d
    Efficacy and safety of sequential therapy with Venetoclax, Azacitidine, and Homoharringtonine in elderly patients with de novo AML: A prospective, single-arm, multicenter, exploratory clinical trial (ChiCTR2500112019)
    P=N/A, N=40, Not yet recruiting, the First Affiliated Hospital, Zhejiang University School of Medicine; The People's Hospital Affiliated to Ningbo University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    3d
    Monitoring of autologous hematopoietic stem cell transplantation for elderly patients with intermediate and high risk acute myeloid leukemia based on second-generation flow cytometry and digital PCR (ChiCTR2600115992)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • cyclophosphamide • melphalan • busulfan
    3d
    A real world Study of Venetoclax exposure and its influencing factors (ChiCTR2500113002)
    P=N/A, N=100, Completed, Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    Venclexta (venetoclax)
    3d
    Efficacy of rosuvastatin combined with azacitidine and venetoclax in the treatment of elderly patients with acute myeloid leukemia(AML) (ChiCTR2500111931)
    P=N/A, N=304, Recruiting, The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; The Ninth People's Hospital Affiliated to Shanghai Jiao To
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    3d
    VOP regimen for the treatment of adult de novo Ph+ B/myeloid mixed phenotype acute leukemia (ChiCTR2500112802)
    P2, N=10, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    Venclexta (venetoclax) • Nailike (olverembatinib)
    3d
    A single center, open label, randomized controlled clinical study on the efficacy and safety of reduced dose azacitidine combined with venetoclax regimen for maintenance therapy of intermediate to adverse risk acute myeloid leukemia (ChiCTR2500114525)
    P2, N=142, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine